Minerva Neurosciences | NERV - Assets

Stock Price
6.27
Daily Change
-0.04 -0.63%
Monthly
45.14%
Yearly
219.90%
Q1 Forecast
2.46

Minerva Neurosciences reported $28.09M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Adma Biologics USD 568.69M 10.31M Sep/2025
ALKERMES USD 2.33B 76.7M Sep/2025
Alterity Therapeutics Limited AUD 27.32M 6.07M Jun/2023
AstraZeneca USD 114.07B 382M Dec/2025
BioCryst Pharmaceuticals USD 446.42M 10.76M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Cipla INR 401.64B 27.77B Sep/2025
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 97.84M 8.68M Sep/2025
CSL USD 39.4B 957M Jun/2025
Dynavax Technologies USD 946.51M 28.06M Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Grifols EUR 23.29B 3.35M Sep/2025
Halozyme Therapeutics USD 2.22B 167.33M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
J&J USD 199.21B 6.39B Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 28.09M 2.33M Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novartis USD 107.29B 2.89B Sep/2025
Novavax USD 1.18B 156.66M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025
Vanda Pharmaceuticals USD 601.14M 23.61M Sep/2025